

Yves J L Bodar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3604354/publications.pdf>

Version: 2024-02-01

14
papers

175
citations

1307366

7
h-index

1199470

12
g-index

14
all docs

14
docs citations

14
times ranked

221
citing authors

#	ARTICLE	IF	CITATIONS
1	Prospective analysis of clinically significant prostate cancer detection with [18F]DCFPyL PET/MRI compared to multiparametric MRI: a comparison with the histopathology in the radical prostatectomy specimen, the ProStaPET study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1731-1742.	3.3	13
2	The clinical characteristics of patients with primary non- α -prostate-specific membrane antigen-expressing prostate cancer on preoperative positron emission tomography/computed tomography. <i>BJU International</i> , 2022, 129, 314-317.	1.3	6
3	Standardised uptake values as determined on prostate-specific membrane antigen positron emission tomography/computed tomography is associated with oncological outcomes in patients with prostate cancer. <i>BJU International</i> , 2022, 129, 768-776.	1.3	7
4	Biochemical Persistence of Prostate-specific Antigen after Robot-assisted Laparoscopic Radical Prostatectomy: Tumor localizations using PSMA PET/CT imaging. <i>Journal of Nuclear Medicine</i> , 2021, 62, jnumed.120.252528.	2.8	11
5	Detection of prostate cancer with 18F-DCFPyL PET/CT compared to final histopathology of radical prostatectomy specimens: is PSMA-targeted biopsy feasible? The DeTeCT trial. <i>World Journal of Urology</i> , 2021, 39, 2439-2446.	1.2	26
6	Pelvic lymph-node staging with 18F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial -. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 509-520.	3.3	60
7	SUVs Are Adequate Measures of Lesional ¹⁸ F-DCFPyL Uptake in Patients with Low Prostate Cancer Disease Burden. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1264-1269.	2.8	2
8	Management impact of 18F-DCFPyL PET/CT in hormone-sensitive prostate cancer patients with biochemical recurrence after definitive treatment: a multicenter retrospective study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2960-2969.	3.3	8
9	Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography in the Evaluation of Initial Response in Candidates Who Underwent Salvage Radiation Therapy after Radical Prostatectomy for Prostate Cancer. <i>Journal of Urology</i> , 2021, 205, 1100-1109.	0.2	4
10	Reply by Authors. <i>Journal of Urology</i> , 2021, 205, 1108-1109.	0.2	0
11	Reply by Authors. <i>Journal of Urology</i> , 2021, 205, 1662-1662.	0.2	0
12	The Predictive Value of Preoperative Negative Prostate Specific Membrane Antigen Positron Emission Tomography Imaging for Lymph Node Metastatic Prostate Cancer. <i>Journal of Urology</i> , 2021, 205, 1655-1662.	0.2	10
13	Repeatability of Quantitative ¹⁸ F-DCFPyL PET/CT Measurements in Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1320-1325.	2.8	22
14	Clinical verification of 18F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer. <i>PLoS ONE</i> , 2020, 15, e0239414.	1.1	6